Meridian Small Cap Growth Fund Highlights Definium Therapeutics (DFTX) for Mental Health Innovation
The Meridian Small Cap Growth Fund, managed by ArrowMark Partners, reported a 21.54% return in Q2 2026 but underperformed its benchmark due to style and factor headwinds. The fund highlighted Definium Therapeutics (NASDAQ:DFTX) as one of its key holdings for the quarter. DFTX is developing an LSD-based therapy for major depressive disorder and generalized anxiety disorder, with positive Phase 3 results reported in July 2026 that exceeded investor expectations. Definium's stock closed at $42.16 per share on July 29, 2026, representing a market cap of $5.6 billion. The company saw strong performance over the past year with a gain of 363.81%, although it declined by -4.59% in one month. Meridian cited DFTX's potential for best-in-class treatment and its pipeline readiness as key reasons for holding the stock. The fund also noted that Definium is positioned to deliver another pivotal readout soon, related to generalized anxiety disorder, which could serve as a major catalyst.